REWIND
2019
Researching Cardiovascular Events with a Weekly Incretin in Diabetes
In 9,901 patients with T2DM mostly without established CV disease, dulaglutide 1.5 mg weekly reduced CV death, non-fatal MI or non-fatal stroke compared with placebo.
Result
Efficacy: 3-point MACEHR 0.88 · P = 0.026
Below 1 favours dulaglutide 1.5 mg weekly, above 1 favours placebo.
Also reported: Benefit consistent in patients with and without established CVD.
- Subtopic
- Primary CV prevention
- Design
- Double-blind RCT, median 5.4 yr
- Relevance
- Important: one of several pillars.
- Source
- Gerstein HC, et al. Lancet. 2019;394(10193):121-130.doi 10.1016/S0140-6736(19)31149-3
Discussion & critique
Extended GLP-1 RA benefit into the primary-prevention population: broadened the indication beyond established CVD.